Pulmonary fibrosis treatment in children - What have we learnt from studies in adults?

Area of Science:

• Pediatric Pulmonology
• Rare Diseases
• Interstitial Lung Disease

Background:

• Pediatric pulmonary fibrosis (PF) is a rare complication of childhood interstitial lung diseases (chILD).
• Current pediatric guidelines for PF management are limited and have not kept pace with adult advancements.
• Anti-fibrotic medications (nintedanib, pirfenidone) are standard in adults but largely unstudied in children.

Purpose of the Study:

• To highlight the critical need for updated pediatric guidelines in PF management.
• To emphasize the lack of research on anti-fibrotic therapies in pediatric populations.
• To advocate for further investigation into current treatments and novel therapies for pediatric PF.

Main Methods:

• Review of existing literature on adult and pediatric PF management.
• Analysis of the current evidence gap for anti-fibrotic drugs in children.
• Identification of areas requiring further clinical trials and research.

Main Results:

• Significant disparity exists between adult and pediatric PF treatment strategies.
• Anti-fibrotic drugs like nintedanib and pirfenidone have not been adequately tested in pediatric patients.
• Recent trials on nintedanib and hydroxychloroquine show promise but underscore the need for more extensive research.

Conclusions:

• There is an urgent need for dedicated pediatric research to guide PF management.
• Evaluating the safety and efficacy of emerging anti-fibrotic treatments in children is paramount.
• Bridging the knowledge gap in pediatric PF is essential for improving patient outcomes.